Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Make a Passover gift and support Jewish journalism. DONATE NOW
Fast Forward

Israeli And American Companies Create Marijuana Inhaler For Sleep

Insomnia sufferers often swear by a puff of marijuana before bed. Now an Israeli company is helping to medicalize the practice with an inhaler that delivers a stable and controlled dose of a cannabis formula that lasts through the night.

i.can.sleep is a joint venture of iCAN:Israel-Cannabis, a group building out the medical marijuana industry in Israel and CannRx, a U.S. corporation that develops medical applications for cannabis.

The joint venture was announced at CannaTech, a conference on medical marijuana happening in Tel Aviv from March 20-22.

“You take a puff or two depending on the dosage and in ten minutes you will be drowsy enough to sleep,” said William Levine of CannRx.

Israel is poised to give final approval to medical marijuana exports in the coming months. According to Kaye, Israel could reap $1 billion in the next two years.

Contact Naomi Zeveloff at [email protected]

This is a moment of great uncertainty. Here’s what you can do about it.

We hope you appreciated this article. Before you go, we’d like to ask you to please support the Forward’s independent Jewish news this Passover.

This is a moment of great uncertainty for the news media, for the Jewish people, and for our sacred democracy. It is a time of confusion and declining trust in public institutions. An era in which we need humans to report facts, conduct investigations that hold power to account, tell stories that matter and share honest discourse on all that divides us.

With no paywall or subscriptions, the Forward is entirely supported by readers like you. Every dollar you give this Passover is invested in the future of the Forward — and telling the American Jewish story fully and fairly.

The Forward doesn’t rely on funding from institutions like governments or your local Jewish federation. There are thousands of readers like you who give us $18 or $36 or $100 each month or year.

Support our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:

  • Credit the Forward
  • Retain our pixel
  • Preserve our canonical link in Google search
  • Add a noindex tag in Google search

See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.